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ABSTRACT
Runt-related transcription factor 1 (RUNX1) is a well-
known master regulator of hematopoietic lineages
but its mechanisms of action are still not fully un-
derstood. Here, we found that RUNX1 localizes on
active chromatin together with Far Upstream Bind-
ing Protein 1 (FUBP1) in human B-cell precursor
lymphoblasts, and that both factors interact in the
same transcriptional regulatory complex. RUNX1 and
FUBP1 chromatin localization identified c-KIT as a
common target gene. We characterized two regula-
tory regions, at +700 bp and +30 kb within the first
intron of c-KIT, bound by both RUNX1 and FUBP1,
and that present active histone marks. Based on
these regions, we proposed a novel FUBP1 FUSE-
like DNA-binding sequence on the +30 kb enhancer.
We demonstrated that FUBP1 and RUNX1 cooper-
ate for the regulation of the expression of the onco-
gene c-KIT. Notably, upregulation of c-KIT expres-
sion by FUBP1 and RUNX1 promotes cell prolifer-
ation and renders cells more resistant to the c-KIT
inhibitor imatinib mesylate, a common therapeutic
drug. These results reveal a new mechanism of ac-
tion of RUNX1 that implicates FUBP1, as a facilitator,
to trigger transcriptional regulation of c-KIT and to
regulate cell proliferation. Deregulation of this regu-
latory mechanism may explain some oncogenic func-
tion of RUNX1 and FUBP1.
INTRODUCTION
Hematopoiesis is an intricate process leading to the differ-
entiation of stem cells into all hematopoietic lineages. It
requires an elaborate network of transcription factors ar-
ticulated with transcriptional regulators, and deregulation
of those networks is implicated in hematologic malignan-
cies. Runt-related transcription factor 1 (RUNX1) is one
of these critical transcription factors playing a prominent
role in hematopoiesis (1,2). RUNX1 is essential for defini-
tive hematopoiesis in early development and adulthood, for
megakaryocyte maturation, T- and B-cell lineages and neu-
ronal development (3–10). In line with its founding role,
loss- or gain-of-function variants of RUNX1 protein pro-
mote hematologic malignancies, notably in the most fre-
quent pediatric subtype of leukemia, the pre-B cell acute
lymphoblastic leukemia (ALL) (1).
RUNX1 functioning is complex and remains a matter
of debate. RUNX1 acts as a transcriptional platform re-
cruiting co-factors thatmodulate its transcriptional activity.
RUNX1 thereby endorses activator or repressor functions
(11,12). Transcriptional activation by RUNX1 requires its
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heterodimerization with Core Binding Factor Beta (CBFB)
(13,14) and the recruitment of co-factors (CBP, P300, etc.),
which display a lineage-specific or ubiquitous expression
pattern, to direct specific biological programs (12,15). Pre-
B ALL emerge from pro-B or pre-B lymphocytes where
RUNX1 is essential for survival and development of B
cell–specified progenitors and for the transition through
the pre-B-cell stage (16). To increase our understanding
about the molecular mechanisms that modulate the tran-
scriptional activity of RUNX1 in pre-B cells and its phys-
iological consequences, we aimed at identifying its specific
partners. Using an unsupervised approach termed RIME
(rapid immunoprecipitation mass spectrometry of endoge-
nous proteins), we identified Far Upstream Element Bind-
ing Protein 1 (FUBP1), an ATP-dependent DNA heli-
case and a transcriptional regulator able to bind single-
stranded DNA (ssDNA) and RNA (17–19), as a poten-
tial RUNX1-regulator. FUBP1 promotes cell proliferation,
inhibits apoptosis, and enhances cell migration by modu-
lating expression of transcripts such as c-MYC (MYC),
P21 (CDKN1A) and Noxa (Pmaip1) (18,20–23). FUBP1 is
also implicated in different processes in RNA regulation
such as post-transcriptional regulation or splicing (19,24–
27). Accordingly, FUBP1 endorses both oncogenic and tu-
mor suppressor roles (21,22,28–31). Importantly, FUBP1
has been recently described as an important regulator of
the expansion and self-renewal of hematopoietic stem cells
(20,32,33). Potential cancer driving mutations of FUBP1
have also been reported in chronic and acute pre-B lympho-
cytic leukemias (34–36).
In this context, we hypothesized that FUBP1 could func-
tionally cooperate with RUNX1. We demonstrate that the
oncogene c-KIT (KIT) is one of FUBP1 and RUNX1 com-
mon target genes. We characterized two regulatory regions
at +700 pb and +30 kb from Transcription Start Site (TSS)
within the first intron of c-KITwhich are bound byRUNX1
and FUBP1, together with active histone marks. c-KIT is a
crucial player in hematopoietic stem cell maintenance and
differentiation (37,38) and presents oncogenic functions
(39,40). We uncovered here that upregulation of c-KIT by
FUBP1 and RUNX1 impacts cell proliferation, which can
be counteracted by the pharmacological c-KIT inhibitor,
imatinib mesylate. Altogether, our data underscore a novel
mechanism of regulation of the oncogene c-KIT that could
play a role in pathophysiological context of RUNX1 and
FUBP1 deregulation.
MATERIALS AND METHODS
Detailed experimental procedures for RNA extrac-
tion, RT-qPCR, generation of stable cell lines, co-
immunoprecipitation, cells sorting, immunoblotting,
chromatin immunoprecipitation (ChIP-Seq), luciferase
assay, molecular simulation, immunophenotyping, and cell
proliferation assays are included in supplemental materials
and methods. Lists of primary antibodies and primers are
outlined in Supplementary Tables S1 and S2.
Cell lines and patients’ cells
Pre-B leukemia cell line Nalm6 (ATCC® CRL-3273™)
was maintained in RPMI-1640 medium containing 10%
heat-inactivated fetal calf serum (FCS) and 1% antibiotics
(penicillin/streptomycin). HEK293 cells (ATCC® CRL-
1573™) were maintained in DMEM/10% FCS/1% antibi-
otics. Bone marrow cells from pre-B acute lymphoblas-
tic leukemia patients were collected at diagnosis, after in-
formed consent had been obtained, in accordance with the
declaration of Helsinki. The protocol was approved by the
ethics committee of Rennes Hospital (France).
Rapid immunoprecipitation mass spectrometry of endoge-
nous proteins (RIME)
RIME was conducted with Nalm6 cells as previously de-
scribed (41). The lysates were incubated with two anti-
RUNX1 and normal rabbit IgG antibodies (Supplemen-
tary Table S1). Peptides were visualized using Scaffold
4 software (http://www.proteomesoftware.com/products/
scaffold/). We selected proteins where the sum of peptide
count for both RUNX1 antibodies is at least three and
higher than 2-fold IgG background. Proteins identified by
only one RUNX1 antibody were excluded.
Proximity ligation assay (PLA)
PLA was carried out with Duolink® In Situ Detec-
tion Reagents and Probes (DUO92007, DUO92002 and
DUO92004, Sigma-Aldrich). The protocol was described in
Debaize et al. (42). Quantification of PLA dots per nucleus
was performed by automatic counting with ImageJ and val-
ues below the assay cut-off (set to two standard deviations
over background signal) were considered negative for the
interaction of interest (42).
Generation of stable cell lines
We used the constructs pLKO1-shFUBP1
(TRCN0000230197, Sigma Aldrich), pLenti-CMV-Puro-
DEST-Flag-FUBP1, pLenti-CMV-Puro-DEST-Halotag-
RUNX1 (from pFN21A #FHC01784, Kazusa collection,
Promega), pSPAX2 (a gift from Didier Trono, Addgene
plasmid #12260) and pCMV-VSV-G (a gift fromBobWein-
berg, Addgene plasmid #8454) (43) to produce lentivirus to
generate HEK293shFUBP1, Nalm6+FUBP1 and Nalm6+RUNX1
Nalm6+RUNX1+FUBP1 stable cell lines. Transfected cells were
selected with 1.1 or 0.25 g/ml puromycin (44). pLenti-
CMV-Puro-DESTwas a gift from Eric Campeau (Addgene
plasmid #17452) (45). For details, see the supplemental
Methods.
Chromatin immunoprecipitation (ChIP) and binding site
analysis
The procedure was adapted from a previous study (46).
Detailed procedure is described in the supplemental meth-
ods. All sequencing data are available at NCBI GEO (
GSE109377). Genomic regions were analyzed with CEAS
(47) and GREAT (48) software to uncover enriched ge-
nomic regions.
11216 Nucleic Acids Research, 2018, Vol. 46, No. 21
Luciferase assay
Genomic DNA fragments derived from the human c-KIT
gene and control DNA were cloned into pGL4.10-luc with
a minimal promoter and transfected in HEK293shFUBP1
cells, in presence of pFN-Halotag-RUNX1 (#FHC01784,
Kazusa collection, Promega) and/or pCDNA-Flag-FUBP1
and supplemented with empty pCDNA vector. For lu-
ciferase assays in Nalm6 cells, the +30 kb enhancer region
was cloned with the minimal promoter into a MSCV Lu-
ciferase PGK-hygro vector (a gift fromScott Lowe, Addgene
plasmid #18782) by the Gibson Assembly® Cloning Kit
(NEB). To produce the +30 kb enhancer-MSCV-luciferase
retrovirus, HEK293 cells were co-transfected with +30
kb enhancer-MSCV-luciferase together with pCMV-VSV-
G and pGag-pol (49). Nalm6 transduced cells were se-
lected with 300 g/mL hygromycin. FUBP1 truncated ex-
pression vector (FUBP1del-CEN) was kindly provided by W.
Keith Miskimins (50). Mutated RUNX1 (RUNX1R174Q,
RUNX1R174Q-T161A) expression vectors were generated by
site-directed mutagenesis.
Molecular simulation
Models of the KH3 FUBP1 subdomain complexed to
single-stranded DNA were based on the nuclear magnetic
resonance (NMR) solution structure 1J4W from the Pro-
tein Data Bank. YASARA software (http://www.yasara.
org), Amber03 force field and standard protocols (51) were
used to produce binding energies.
Immunophenotyping
Intracellular and surface stainings of c-KIT protein were
performed by flow cytometry using APC-Mouse-Anti-
Human CD117 antibody (Clone YB5.B8, BD Biosciences).
Cell proliferation and cell analysis
Proliferation assays were done by automatic counting with
a Cellometer (Nexcelom). Apoptosis/necrosis analyses and
inhibition assays were performed with automatic counting
following Hoechst, propidium iodine and Yo-Pro stainings.
Xenograft transplantation and survival analysis
NOD/scid IL2 Rgnull mice (Charles River Laboratories,
France) were maintained in the ARCHE Animal Hous-
ing Center (Rennes, France). Animal experiments were per-
formed after authorization by the French Research Min-
istry, and according to European regulation. Four-week-
old mice received two intraperitoneal injections of 20 g/g
busulfan (60 mg/10 ml, Pierre Fabre) on 2 days. They were
then allowed to rest for 2 days before intravenous retro-
orbital injection of 100 000 cells as previously described
(44).
RESULTS
RUNX1 ChIP-Seq signal is enriched within transcriptionally
active chromatin regions in pre-B cells
To investigate the transcriptional role of RUNX1 in hu-
man pre-B cells, we mapped its genome-wide distribution
by chromatin immunoprecipitation followed by sequencing
(ChIP-Seq) in pre-B Nalm6 cells and bone marrow cells
isolated from pre-B leukemic patients. Antibody against
RUNX1 was validated in our models (Supplementary Fig-
ure S1A and B). To correlate RUNX1 engagement with
chromatin activity in Nalm6 cells, we ran ChIP-Seq of hi-
stones H3K4me1, H3K4me3 and H3K27ac, respectively
markers of active/poised enhancers, active/poised promot-
ers and active promoters/enhancers.
Replicates of RUNX1 ChIP-Seq in Nalm6 cells retrieved
5514 common peaks, 69% (3803 peaks) of which are also
found in RUNX1 ChIP-Seq peaks in at least two out of
three pre-B leukemic patients (Figure 1A). Those 3803
peaks were assigned to 2651 genes (Supplementary Table
S3). RUNX1-bound regions were highly enriched in pro-
moters (–1 kb from the TSS) and in 5′UTR regions (Fig-
ure 1B). RUNX1-bound regions were associated with en-
riched H3K4me3 and H3K27ac signals in promoters, and
with H3K4me1 and H3K27ac signals in genomic regions
excluding promoters (no-promoter regions) (Figure 1C). Fi-
nally, the average RUNX1 signal peaked at regions positive
for H3K4me3, H3K4me1 and H3K27ac but not at random
regions (Figure 1D). Ontology analyses of these genes re-
veal an enrichment in biological processes related to tran-
scription regulation, cell cycle regulation and a variety of
hematologic processes (Figure 1E and Supplementary Ta-
ble S4). Cancer, cardiovascular disease, and hematopoietic
disease are also enriched in disease ontology analysis (Fig-
ure 1E and Supplementary Table S4). Altogether, our data
show that RUNX1 localizes on chromatin in transcription-
ally active chromatin regions mainly in promoter and en-
hancer regions in human pre-B cells.
FUBP1 protein interacts with RUNX1 in hematopoietic lin-
eages
To identify RUNX1 co-factors able to modulate its tran-
scription activity, we performed immunoprecipitations of
endogenous RUNX1 protein in pre-B Nalm6 cells with two
different antibodies followed bymass spectrometry (RIME)
(41) (Figure 2A). We identified 20 RUNX1-associated pro-
teins (Supplementary Table S5). RUNX1 was recovered
with the highest number of peptides (18–21 peptides).
CBFB, a well-known transcriptional cooperating factor re-
sponsible for RUNX1 stabilization on chromatin (14), was
also recovered with 3–4 peptides. Together, these results
validated the RUNX1-RIME approach. Interestingly, 9–14
peptides from the Far Upstream Element Binding Protein
1 (FUBP1) were identified, although FUBP1 peptides were
also enriched with control IgGs but to a lower extent (Fig-
ure 2A). Given that RUNX1 and FUBP1 share common
roles in hematopoietic lineages, a potential functional inter-
action between these two proteins was further investigated.
We confirmed the RIME-based results using a tar-
geted approach. Flag-tagged FUBP1 and Halotag-tagged
RUNX1 were co-expressed in HEK293 cells. We found
that Halotag-RUNX1 co-immunoprecipitated with Flag-
FUBP1 using an anti-Flag antibody (Figure 2B) and
conversely, Flag-FUBP1 co-immunoprecipitated with
Halotag-RUNX1 using an anti-Halotag antibody (Sup-
plementary Figure S1C). We then interrogated whether
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Figure 1. RUNX1ChIP-Seq signals are enriched within transcriptionally active chromatin regions. (A) Venn-diagrams presenting the intersection between
RUNX1 binding regions in both replicates in Nalm6 cells, and bone marrow mononuclear cells isolated from three pre-B ALL patients. (B) Analyses of
RUNX1ChIP-Seq-enriched signals for pre-BNalm6 cells and bone marrowmononuclear cells isolated from a pre-B acute lymphoblastic leukemia patient.
ChIP-Seq readswere aligned to the reference human genome versionGRCh37 (hg19). Analyses with the cis-regulatory ElementAnnotation System (CEAS)
(47) software of RUNX1 ChIP-Seq provided RUNX1-bound regions enrichment in different genomic regions compared to the whole genome. (Ci and
Cii) Read density plots for H3K4me1, H3K4me3 and H3K27ac enrichment centered around RUNX1 binding sites over a 3 kb window from RUNX1
Chip-Seq in Nalm6 cells, in promoter regions ([–4000 +1000] from TSS of annotated genes) (Ci) or without promoter regions (Cii). (D) Read density plots
for RUNX1 signal around H3K4me1, H3K27ac, H3K4me3 regions over a 3 kb window and random regions of similar lengths in Nalm6 cells. The graph
shows that the averageRUNX1 signal peaked at regions positive forH3K4me3,H3K4me1 andH3K27ac. (E) Annotation enrichments of the 2651 potential
RUNX1 target genes identified with DAVID (81) for biological process and GREAT (48) for disease ontology were shown. We selected 5 non-redundant
annotations among the 10 most significant.
RUNX1 and FUBP1 colocalize under physiological con-
ditions in human pre-B cells. To that aim, we used the
Proximity Ligation Assay (PLA), which is a powerful
technique to detect endogenous protein–protein spatial
proximity (Figure 2C and D) (42). As expected (13,14),
PLA dots were observed with RUNX1 and CBFB proteins
in Nalm6 cells, thereby validating the approach. Impor-
tantly, we detected a close proximity between RUNX1 and
FUBP1 proteins in the nuclear compartment (Figure 2C)
in accordance with their transcriptional function (52,53).
Interestingly, we also detected a close molecular proximity
between FUBP1 and CBFB proteins, suggesting that
RUNX1, FUBP1 and CBFB associate in one or several
regulatory complexes. The absence of any detectable PLA
signal between FUBP1 and other transcription factors
(TFAP4, USF1) strengthened the specificity of the inter-
actions observed between FUBP1, RUNX1 and CBFB
(Figure 2C). Additional PLA analyses in Nalm6 cells
demonstrated that FUBP1 is in close molecular proximity
with CBP and P300, two transcriptional co-activators
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Figure 2. FUBP1 protein interacts with RUNX1 in hematopoietic lineages. (A) Number of peptides from RUNX1 (49 kDa), CBFB (22 kDa) and FUBP1
(68 kDa) proteins identified by RIME (rapid immunoprecipitation mass spectrometry of endogenous proteins) with RUNX1 or immunoglobulin G (IgG)
control in pre-B lymphoblastic Nalm6 cells. The lysates were incubated with 10 g of anti-RUNX1 (ab23980, Abcam), 5 g of anti-RUNX1 (HPA004176,
Sigma Aldrich) or with 10 g of normal anti-IgG (sc2027, Santa Cruz Biotechnology). (B) Co-immunoprecipitation (IP) using anti-Flag antibody (M2
clone) in HEK293 cells expressing Halotag-RUNX1 and/or Flag-FUBP1. Western blots were performed with RUNX1 and FUBP1 antibodies. Similar
levels of IgG heavy chains in both IP-Flag lanes were used as loading control. (Ci) Representative images of a Proximity Ligation Assay (PLA) in Nalm6
cells. Four pairs of antibodies were used as indicated (references of the antibodies are listed in the Supplementary Table S1). Nuclei were stained by DAPI
and appeared in blue. Colocalization of proteins, visualized by PLA dots, appeared in green. (Cii and Ciii) Quantitation of protein co-localization per
nucleus–visualized by PLA dots- in Nalm6 cells, presented with the mean values ± S.D. The value of the mean is indicated at the top of each scatter dot
plot. Quantitation of PLA dots was performed by an automatic counting with ImageJ as published by Debaize et al. (42). Positive controls (named total
RUNX1 or total FUBP1, where primary antibodies against two different epitopes of RUNX1 or FUBP1 were used) and negative controls (either anti-
RUNX1 alone or anti-FUBP1 alone) were included. Here, the positive threshold value represented by the dotted line (set at two S.D over the background
signal) is 4.3 dots. One representative experiment of at least two independent experiments is shown. (Ciii) CBP and P300 are co-activators that are well
known to interact with RUNX1. (D) Quantitation of protein colocalization per nucleus (visualized by PLA dots) in human mononuclear cells from bone
marrow of three pre-B acute lymphoblastic leukemia patients, presented with the mean values. The value of the mean is indicated at the top of each scatter
dot plot. Here, the positive threshold value represented by the dotted line is 1.7 dots.
known to be part of RUNX1 complexes (54) (Figure 2C)
suggesting that FUBP1 and RUNX1 can colocalize in a
same transcriptional complex. Importantly, the proximity
between FUBP1, RUNX1 and CBFB were confirmed in
bone marrow cells from all three tested pre-B leukemic pa-
tients (Figure 2D). Finally, comparable results for FUBP1
and RUNX1 proximity were obtained in other pre-B
cell lines (BJAB and REH cells) (Supplementary Figure
S1D). Interestingly, we demonstrated a proximity between
FUBP1 and the fusion protein ETV6-RUNX1 in REH
cells (Supplementary Figure S1D). Moreover, we evidenced
a spatial proximity between FUBP1 and RUNX1 in human
CD34+ hematopoietic stem and progenitor cells (Sup-
plementary Figure S1E). Altogether, these data indicate
that FUBP1 is likely to influence RUNX1 transcriptional
activity in blood cells.
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FUBP1 and RUNX1 regulate c-KIT transcription by binding
to a common intronic enhancer in the c-KIT gene
Among the 2651 genes putatively regulated by RUNX1
was c-KIT. Since c-KIT oncogene plays a central role in
cell growth control and stimulation of proliferation of
hematopoietic stem cells and early committed hematopoi-
etic lineage cells (38,55), we decided to work further
on the regulation of this gene by RUNX1. Upregula-
tion of RUNX1 (in Nalm6+RUNX1) modulated positively c-
KIT mRNA expression (Figure 3A, Supplementary Fig-
ure S2A). Interestingly, enforced expression of FUBP1 (in
Nalm6+FUBP1) strongly upregulated c-KIT expression with
an opposite profile upon depletion of FUBP1, suggesting
that RUNX1 and FUBP1 could participate in c-KIT tran-
scription (Figure 3A, Supplementary Figure S2A and B).
We then analyzed ChIP-Seq data for RUNX1 and hi-
stones marks along the c-KIT gene in pre-B Nalm6 and
bone marrow cells from leukemic patients. We identified
two strong RUNX1 binding regions in the first intron of c-
KIT: one at +700 bp and another one at +30 kb from TSS,
that overlapped respectively with H3K4me3 and H3K4me1
marks and displayed H3K27ac marks, indicating active
chromatin regions (Figure 3B).
To investigate the binding of FUBP1 on those two chro-
matin regions, FUBP1 antibody was first validated for IP in
HEK293+FUBP1 (Supplementary Figure S2C) and tested for
ChIP-qPCR on CDKN1A and MYC loci. Very few target
regions, including CDKN1A and MYC loci, are described
as bound by FUBP1, with results varying with the models
(19,20,56–58). We found that FUBP1 binds to CDKN1A
promoter in Nalm6control compared to Nalm6shFUBP1, but
not to the –1.5kb MYC promoter (Supplementary Figure
S2D). These results validate FUBP1 antibody for ChIP.
Bindings of RUNX1 and FUBP1 to both c-KIT intronic
regions were validated by ChIP-qPCR and showed higher
fold enrichment at the +30 kb enhancer compared to the
+700 bp site (Figure 3C). Importantly, the +30 kb enhancer
conferred an additive responsiveness to transcription acti-
vation upon RUNX1 and FUBP1 transfection in luciferase
reporter assays performed in HEK293shFUBP1 cells (Fig-
ure 3D), in which endogenous FUBP1 was depleted (Sup-
plementary Figure S2E). Conversely, the promoter region
(+700 bp) mostly responded to RUNX1 expression (Fig-
ure 3D). We therefore focused on the +30 kb enhancer re-
gion (500-nucleotide-long). StableRUNX1 or FUBP1 over-
expression in Nalm6 cells demonstrated the responsiveness
of the +30 kb enhancer of c-KIT to transcription activation
upon RUNX1 or FUBP1 expression. Moreover, the com-
bination of RUNX1 and FUBP1 shows synergetic effect on
the c-KIT +30 kb enhancer (Figure 3E). Altogether, these
data demonstrate that the c-KIT enhancer at +30 kb is con-
trolled by RUNX1, FUBP1 and more importantly RUNX1
together with FUBP1 in pre-B lymphoblasts, suggesting a
cooperativity between those two transcription regulators.
RUNX1 and FUBP1 cooperate for the regulation of the +30
kb enhancer of c-KIT
To address the question of the cooperativity between
RUNX1 and FUBP1 for the regulation of c-KIT expres-
sion (Figure 4A), we conducted RUNX1 ChIP-qPCR on
+30 kb enhancer upon presence (in Nalm6control) or deple-
tion of FUBP1 (in Nalm6shFUBP1). We showed that there is
∼4.5-fold more RUNX1 bound to the +30 kb enhancer in
presence of FUBP1 than upon depletion of FUBP1.
We next investigated the impact of RUNX1 and FUBP1
modulation on histones marks at the promoter and the en-
hancer. We showed that enforced expression of RUNX1,
FUBP1 or both RUNX1 with FUBP1 increases H3K4me1
andH3K27ac signal at the +30 kb enhancer, andH3K4me3
andH3K27ac at the promoter (Figure 4B). Importantly, the
strong increase of H3K27ac signal when both RUNX1 and
FUBP1 are overexpressed indicates a strong activation of
the gene transcription (Figure 4B). Those data demonstrate
that RUNX1 and FUBP1 cooperate at the +30 kb c-KIT
enhancer and modulate the chromatin state at this region.
Identification of RUNX1 and FUBP1 DNA binding motifs
within the +30 kb enhancer of c-KIT
Analysis of the +30 kb c-KIT enhancer (500-nucleotide-
long) revealed the presence a 29-nucleotide-long FUSE-
like sequence homologous to the sole FUBP1-binding mo-
tif described so far and called the FUSE sequence (18,59)
(Figure 5A). We also predicted two RUNX1 binding sites
that displayed high sequence conservation with theRUNX1
consensus motif 5′-TGTGGT-3′ (60,61). To investigate the
importance of these sequences in RUNX1- and FUBP1-
dependent transcriptional activation, we mutated RUNX1-
and FUBP1-predicted binding sites in +30 kb enhancer lu-
ciferase reporter vector. Mutations of those predicted bind-
ing sequences resulted in the abrogation of the effects of
RUNX1 and FUBP1, indicating that identified RUNX1-
andFUBP1FUSE-like binding sites are functional and that
each element is required for the transcriptional activation of
the +30 kb enhancer of c-KIT (Figure 5B).
Additionally, DNA-binding mutants of RUNX1 protein
(RUNX1R174Q and RUNX1T161A,R174Q) (62,63) and trunca-
tion of FUBP1 central DNA-binding domain encompass-
ing four K-Homology (KH) subdomains (50) reduced the
transcription activity of the +30kb enhancer in luciferase re-
porter assays (Figure 5C). Those results demonstrated that
RUNX1- and FUBP1-DNA-binding domains are neces-
sary for a maximal transcriptional activation of the +30 kb
enhancer of c-KIT.
Since FUBP1 requires two functional subdomains (KH3
and KH4) to bind DNA (18,59,64,65) (Figure 5A), and
because FUBP1-DNA binding sequences are documented
only for a few genes (19,64), we investigated the binding
energies of the KH3 and KH4 subdomains on the +30
kb c-KIT enhancer (Figure 5D). We generated 12 struc-
tural models of KH3 binding to single-stranded-DNA slid-
ing sequences in 3′ from the theoretical positioning of the
KH4 subdomain on the 5′-TATTCC-3′ sequence. A maxi-
mal binding energy was measured for the AT-rich sequence
5′-ATATAAA-3′ located in 3′ at 7-nucleotide-apart from
theKH4-bound sequence. This novelKH3-bound sequence
is coherent with the previously described AU-rich FUBP1
RNA-bound sequence (66) and its position relative to the
KH4-bound motif is fully consistent with the inter-domain
distance suggested by previous structural studies (59). The
structural model of KH3 binding to 5′-ATATAAA-3′ se-
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Figure 3. FUBP1 and RUNX1 regulate c-KIT transcription by binding to a common intronic enhancer in the c-KIT gene. (A) Expression data analyses of
c-KIT mRNA. RT-qPCR were performed in biological triplicate in Nalm6 cells overexpressing FUBP1 or RUNX1 (see Supplementary Figure S2A) and
expression data are given compared to Nalm6control cells after normalizing withGAPDHmRNA (error bars are S.D.). *P< 0.05, **P< 0.01, ***P< 0.001
inMann–Whitney tests. (B) Genomic tracks displayed ChIP-Seq data for RUNX1 and the histones H3K4me3, H3K27ac and H3K4me1 fromNalm6 cells
(2 replicates) and bone marrowmononuclear cells isolated from three pre-B acute lymphoblastic leukemia patient across the first 35 kb of the human c-KIT
gene (NM 000222). ChIP-Seq data were acquired by Illumina sequencing and visualized with Integrated Genome Browser 9.0.0 (82). ChIP-Seq reads were
aligned to the reference human genome version GRCh37 (hg19). Both genomic regions of c-KIT gene that were associated with active histone marks are
located within the first intron, one in a promoter region (+700 pb from TSS) and the another in an enhancer region (+30 kb from TSS) and are indicated
by boxes. (C) ChIP-qPCR performed on samples fromNalm6 cells using a specific anti-RUNX1 (n= 3), anti-FUBP1 (n= 3) or a non-specific control IgG.
ChIP-qPCR shows fold enrichment for c-KIT promoter (+700 pb) and enhancer (+30 kb) regulatory regions. Histogram indicates the means with S.D. of
the fold enrichment of peaks relative to IgG. (D) Luciferase assays with a vector containing the c-KIT promoter or enhancer regions downstream aminimal
promoter and a luciferase ORF, in presence of RUNX1 and FUBP1 expressing vectors in HEK293shFUBP1 cells (see Supplementary Figure S2E). Note that
theHEK293shFUBP1 cells do not express RUNX1 and that the FUBP1 expression vector is resistant to shFUBP1. Luciferase levels (firefly luciferase/Renilla
luciferase) are represented using a scatter dot plot indicating the means and S.D. of at least 4 independent experiments. NS: non-significant, * < 0.05 in
Mann–Whitney tests. (E) Luciferase assays with a vector containing the c-KIT enhancer regions downstream a minimal promoter and a luciferase ORF,
in presence of RUNX1 and FUBP1 expressing vectors in Nalm6control, Nalm6+RUNX1, Nalm6+FUBP1 and Nalm6+RUNX1+FUBP1 cells. Luciferase levels are
represented using a scatter dot plot indicating the means and S.D. of at least four independent experiments (i.e. each dot represents an independent stable
cell line). The expression level of RUNX1 is similar in Nalm6+RUNX1 and Nalm6+RUNX1+FUBP1. The expression level of FUBP1 is similar in Nalm6+FUBP1
and Nalm6+RUNX1+FUBP1 (refer to Figure 6A, Supplementary Figure S3B). NS: non-significant, *P < 0.05 in Mann–Whitney tests.
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Figure 4. FUBP1 is a facilitator of the binding of RUNX1 on the +30kb enhancer of c-KIT. (A) ChIP-qPCR performed on samples fromNalm6control and
Nalm6shFUBP1 cells using a specific anti-RUNX1 (n= 3) or a non-specific control IgG (n= 3) at the c-KIT enhancer (+30 kb) regulatory regions. Histogram
indicates the means with S.D. of the fold enrichment of peaks relative to IgG. (B) ChIP-qPCR performed on samples from Nalm6control, Nalm6+RUNX1,
Nalm6+FUBP1 and Nalm6+RUNX1+FUBP1 cells using specific anti-histones H3K4me3, H3K27ac and H3K4me1 at the c-KIT promoter (+700 bp) and
enhancer (+30 kb) regulatory regions. Histogram indicates the fold enrichment of peaks relative to IgG.
quence indicates that stabilization of this complex is mainly
driven through hydrophobic contacts with the ssDNA nu-
cleobases and electrostatic interactions with the ssDNA
sugar phosphate backbone of amino-acids located in a
groove (Figure 5D).
Hence, we have identified the RUNX1 binding sequences
and a new FUBP1 FUSE-like binding sequence, where
KH4 and KH3 FUBP1-subdomains bind on the intronic
enhancer of c-KIT, which functionally regulate c-KIT ex-
pression.
FUBP1 and RUNX1 exacerbate the c-KIT pathway and con-
tribute to cell proliferation
To further investigate the cooperative role of FUBP1 and
RUNX1 in c-KIT regulation, we compared c-KIT level and
functionality in pre-B Nalm6 cells overexpressing FUBP1
and/or RUNX1. c-KIT transcript levels were elevated in
Nalm6+RUNX1, Nalm6+FUBP1 and in Nalm6+RUNX1+FUBP1
stable cell lines (Figure 6A). Furthermore, we identified a
positive correlation between FUBP1 and c-KITmRNA lev-
els as well as between RUNX1 and c-KIT mRNAs (Fig-
ure 6B). Comparable results were obtained in REH cells
and ETV6-RUNX1 leukemia patient biopsies (data from
St. Jude Children’s Research Hospital––Pediatric Cancer
Data Portal) (67) (Supplementary Figure S3A). Impor-
tantly, the presence of RUNX1 reinforces the regulation of
c-KIT by FUBP1 (Figure 6B). The c-KIT protein steady-
state levels were also elevated (Supplementary Figure S3B).
This phenotype was more pronounced for both intracel-
lular and surface c-KIT in Nalm6 cells overexpressing
FUBP1 or FUBP1+RUNX1 as shown by FACS (Figure
6C). Upon binding of the c-KIT ligand, the Stem Cell Fac-
tor (SCF), c-KIT dimerizes and autophosphorylates allow-
ing the activation of its downstream pathways, including
the ERK MAP-kinase pathway (68). Hence, to investigate
the functionality of c-KIT, we next analyzed phospho-c-
KIT in Nalm6control and Nalm6+FUBP1 cells treated with
SCF. Nalm6+FUBP1 cells showed a faster response to SCF
than control cells with higher levels of phospho-c-KIT and
phospho-ERK1/2 after 5 minutes of treatment (Supple-
mentary Figure S3C). In addition, SCF induces c-KIT in-
ternalization and degradation, one of the hallmarks of c-
KIT functionality (69). Following SCF stimulation, c-KIT
was more intensively internalized in Nalm6+FUBP1 and es-
pecially in Nalm6+RUNX1+FUBP1 than in Nalm6control cells.
These results suggest that a stronger biological response to
SCF is elicited by overexpressingRUNX1 andFUBP1 (Fig-
ure 6D).
Having demonstrated that FUBP1 and RUNX1 reg-
ulate c-KIT and that c-KIT is properly functional, we
next addressed the question of the physiological conse-
quence of this regulation. Nalm6+FUBP1, Nalm6+RUNX1 and
Nalm6+RUNX1+FUBP1 cells presented a higher proliferation
rate than Nalm6control cells (Figure 7A). This result was
consistent with the proliferation arrest induced by FUBP1
loss-of-function (32,70). The gain-in-proliferation pheno-
type was slightly exacerbated in presence of SCF (Figure
7A) as anticipated from the surface membrane c-KIT inter-
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Figure 5. Identification of RUNX1 and FUBP1DNA binding motifs within the +30 kb enhancer of c-KIT. (A) Schematic representation of two functional
subdomains (KH3 andKH4) of FUBP1 required for its binding to the FUSE sequence located –1.5 kb upstream the c-MYC P1 promoter (20,59). Potential
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nalization (Figure 6D), even if Nalm6 cells are not fully de-
pendent on SCF for proliferation. Apoptosis and necrosis
were minimal in all those cell lines (Supplementary Figure
S3D). A BrdU pulse-chase assay allowed us to correlate this
increase in proliferation rate to an acceleration of cell cycle
in Nalm6+FUBP1, Nalm6+RUNX1 and Nalm6+RUNX1+FUBP1
cells compared to Nalm6control cells (Supplementary Fig-
ure S3E). Finally, mice xenografted with Nalm6+FUBP1,
Nalm6+RUNX1 or Nalm6+RUNX1+FUBP1 cells presented a re-
duced survival compared to mice injected with Nalm6control
cells (Figure 7B). Altogether, these data demonstrate that
enforced expression of FUBP1 and RUNX1 regulate c-KIT
expression and subsequent cell proliferation.
We next evaluated Nalm6 cells responsiveness to a c-KIT
inhibitor, the imatinib mesylate (71). While Nalm6control,
Nalm6+FUBP1, Nalm6+RUNX1 andNalm6+RUNX1+FUBP1 cells
were sensitive to imatinib mesylate at a standard concen-
tration of 1 M as shown by the decreased phosphory-
lation of c-KIT and of downstream targets such as ERK
and AKT (Supplementary Figure S3F), cells overexpress-
ing FUBP1, RUNX1, alone or together, were less sensitive
to the inhibitor in a proliferation assay beyond the dose of 1
M (Figure 7C). This result demonstrates that FUBP1 and
RUNX1 levels can impact on the sensitivity of the cells to a
c-KIT inhibitor.
DISCUSSION
In our search for identifying transcriptional co-factors of
RUNX1and deciphering its function, we demonstrated that
RUNX1 and FUBP1 co-immunoprecipitated and are phys-
ically located close to each other on active chromatin of hu-
man hematopoietic cells.
Examination of RUNX1 genome-wide distribution to-
gether with gene expression data led us to propose that
the oncogene c-KIT is commonly activated by RUNX1 and
FUBP1. Moreover, we identified two regulatory regions in
the first intron of c-KIT (the +700 bp promoter and the +30
kb enhancer regions) that are bound by RUNX1, FUBP1
and present active histonemarks. Interestingly, a very recent
study in AML1-ETO acute myeloid leukemia spotted iden-
tical regulatory regions in c-KIT gene bound by RUNX1
(or AML1) and the fusion protein AML1-ETO (72). The
role of the transcriptional regulators RUNX1 and FUBP1
in a potential interplay between c-KIT enhancer and pro-
moter has not been addressed yet. However, Tian et al.
identified a DNA-loop between the promoter and the +30
kb enhancer of c-KIT that plays a significant role in tran-
scriptional regulation (72). Since FUBP1 induces a similar
promoter-enhancer loop in the c-MYC gene through inter-
action with TFIIH (73), we propose that FUBP1 could trig-
ger the formation of such a DNA-loop at the c-KIT locus.
Optimal FUBP1 binding sequences are still a matter of
debate (19,22,59,64,74). Here, we benefit from the func-
tional c-KIT enhancer to bring new insights on novel
FUBP1 DNA-binding sequences. Analysis of the +30 kb
c-KIT enhancer, by molecular biology and structural mod-
eling, allows us to report a c-KIT FUSE-like sequence
encompassing the KH4 binding sequence (retrieved from
the c-MYC promoter (18,59)), a 7-nucleotide-long spacer
that may not interact with FUBP1 as described previously
(59), and an AT-rich sequence bound by the KH3 subdo-
main consistently with FUBP1-bound AU-rich sequences
described previously (66).
c-KIT encodes a tyrosine kinase receptor and is expressed
in hematopoietic stem and progenitor cells (38,75). Binding
of SCF to the c-KIT receptor triggers a cascade of signal-
ing pathways resulting in the regulation of apoptosis, pro-
liferation and differentiation (68). Inappropriate c-KIT ex-
pression bears oncogenic consequences. c-KIT gene is found
overexpressed in human leukemia from myeloid and some
lymphoid lineages (67,68,76,77) and constitutive c-KIT ac-
tivity triggers lymphoblastic leukemia in mouse model (78).
Our findings suggest a new mechanism for the control of
cell proliferation via the fine-tuned regulation of c-KIT by
FUBP1 and to a lesser extent RUNX1. Importantly, we
demonstrated that FUBP1-induced c-KIT expression pro-
duces a functional protein with increased tyrosine phospho-
rylation of its substrates and faster internalization follow-
ing SCF stimulation. The phenotype on proliferation asso-
ciated to c-KIT pathway activation is reinforced when both
FUBP1 and RUNX1 are overexpressed. FUBP1 mRNA
level was shown to be significantly elevated in leukemia stem
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
c-KIT FUSE-like sequence within the +30 kb c-KIT intronic enhancer (identified by in silico analysis) is provided. Nucleic acid homology is represented by
asterisks (*). The c-KIT FUSE-like sequence showed 48.2% homology compared to the FUSE sequence according to CLUSTAL 2.1 Multiple Sequence
Alignments software (83). (Bi) Scheme of the human c-KIT enhancer. Predicted RUNX1 binding sites with more than 80% sequence conservation from
Jaspar RUNX1matrix (MA0002.1) have been selected with Jaspar software (61). (Bii) Luciferase assays with a vector full-length or mutated variants of the
+30 kb c-KIT enhancer downstream a minimal promoter and a luciferase ORF, in presence of RUNX1 and FUBP1 expressing vectors were performed in
HEK293shFUBP1 cells. In the mutated variants, RUNX1 predicted binding sites 5′-GGTGTTGTG-3′ and 5′-ATTGTGGTTA-3′ were site-directed mutated
or the predicted FUBP1 FUSE-like binding sequence was deleted. Luciferase levels (firefly luciferase/Renilla luciferase) are represented using a bar chart-
scatter dot plot indicating the means with S.D. of at least four independent experiments. Luciferase activities are normalized to the control (–). NS: non-
significant, *P< 0.05 in Mann–Whitney tests. (Ci) Scheme of RUNX1 and FUBP1 proteins with indication of the position of mutations for RUNX1, and
truncated FUBP1. ID: inhibition domain, TE/TD: transactivation domain. (Cii) Luciferase assays with a vector containing the +30 kb c-KIT enhancer
downstream a minimal promoter and a luciferase ORF, in presence of RUNX1 mutants and truncated FUBP1 expressing vectors were performed in
HEK293shFUBP1 cells. Luciferase levels are represented as in Bii.(Di) Binding energies (kcal.mol-1) of the KH3 subdomain of FUBP1 protein with the c-
KIT FUSE-like sequence. Red framed sequence corresponds to the positioning of KH4 subdomain by analogy to the FUSE sequence retrieved on c-MYC
promoter associated to the solution NMR structure of KH4 (PDB ID: 1J4W). Maximum binding energy of KH3 is computed for 5′-ATATAAA-3′. (Dii)
Structural model for the most stable complex formed by the KH3 subdomain with the c-KIT +30 kb enhancer sequence. Protein is shown as a molecular
surface colored according to hydrophobicity (84) (white for hydrophilic, yellow for hydrophobic), electrostatic potentials are represented as iso-surfaces
(–50kTe in red and +50kTe in blue). Tilt observed between second (dT) and third (dA) bases originates from the position of the KH3 first alpha-helix, as it
was observed in the experimental structure used as structural template for modeling. (Diii) Schematic representation of the amino-acids of KH3 subdomain
of FUBP1 involved in the binding to the FUSE sequence.
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Figure 6. FUBP1 and RUNX1 exacerbate the c-KIT pathway. (A) mRNA levels analyzed by RT-qPCR of c-KIT, FUBP1, and RUNX1 in Nalm6control,
Nalm6+RUNX1, Nalm6+FUBP1, and Nalm6+RUNX1+FUBP1 cells. Results are presented in terms of a fold change after normalizing with GAPDH mRNA.
Each dot represents a biological replicate. NS: non-significant, **P< 0.01, ***P< 0.001, ****P< 0.0001 inMann–Whitney tests. (B) Correlation between
FUBP1 and KIT mRNA levels from different transduced Nalm6+FUBP1 and Nalm6+RUNX1+FUBP1 stable cell lines, and correlation between RUNX1 and
KIT mRNA levels in Nalm6+RUNX1 and Nalm6+RUNX1+FUBP1 cells are presented. P-value (p), Pearson correlation coefficient (r), slope of the correlation
curve (slope), and number of biological replicates analyzed (n) are indicated. (C) FACS analyses following c-KIT (CD117) intracellular and surface staining
in Nalm6control, Nalm6+RUNX1, Nalm6+FUBP1, or Nalm6+RUNX1+FUBP1 cells. The c-KIT expression was assessed in comparison with the control isotype
staining. A representative analysis of the KIT surface staining is shown on the left. Percentage of the mean fluorescence intensity (MFI) is presented on
the right panel (n= 4–8 per group) after normalizing with Nalm6control cells. Statistical significance was assessed compared to Nalm6control cells byMann–
Whitney tests (NS: non-significant, *P < 0.05, **P < 0.01, ***P < 0 .001). (D) Mean fluorescence intensity (MFI) analyzed by FACS from Nalm6control,
Nalm6+RUNX1, Nalm6+FUBP1, and Nalm6+RUNX1+FUBP1 cells following SCF treatment (0 or 100 ng/ml of SCF were added in the culture media and
incubated 5 min at 37◦C) and c-KIT surface staining. SCF induces c-KIT internalization and degradation, one of the hallmarks of c-KIT functionality
(69). Statistical significance was assessed compared to untreated cells (without SCF) by Mann–Whitney tests (NS: non-significant, *P < 0.05, **P< 0.01,
***P < 0 .001).
cell-enriched cell populations and in some lymphoblastic
leukemia subtypes (data from St. Jude Children’s Research
Hospital) (67,79) as well as RUNX1 (80). Here, we pro-
posed for the first time a rationale for oncogenic function of
FUBP1 in leukemia. Therefore, since RUNX1, FUBP1 and
c-KIT are overexpressed in some subtypes of leukemia, ab-
normalities in this regulatory network could participate in
the onset or the maintenance of RUNX1-related leukemia.
We hypothesize that the c-KIT pathway may be impaired in
those models and draw attention to the possible decrease in
sensitivity under c-KIT inhibitor treatment.
In conclusion, we demonstrate a regulatory network
involving two transcriptional regulators, RUNX1 and
FUBP1, in the control of the +30 kb c-KIT enhancer.
FUBP1 and RUNX1 colocalize on active chromatin, coop-
erate for regulating c-KIT transcription, and promote cell
cycle progression. Although our study focuses on the role of
the cooperativity between RUNX1 and FUBP1 in the regu-
lation of c-KIT, we can envision that this partnership most
likely impacts on other target genes. Deregulation of this
regulatory mechanism may explain some oncogenic func-
tion of RUNX1 and FUBP1.
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Figure 7. FUBP1 and RUNX1 contribute to c-KIT-dependent cell proliferation. (A) Proliferation curves from Nalm6control (n = 5), Nalm6+RUNX1 (n =
4), Nalm6+FUBP1 (n= 5), Nalm6+RUNX1+FUBP1 (n= 5) cells exposed to 0 or 100 ng/ml of SCF the first day (day 0). Histogram (on the right) represents the
number (means with S.D.) of cells at day 7. Statistical significance was assessed compared to Nalm6control byMann–Whitney tests (NS: non-significant, *P
< 0.05, **P < 0.01). (B) Survival curves from immunodeficient NOD/scid IL2 Rgnull mice xenografted with 100 000 cells: Nalm6control, Nalm6+RUNX1,
Nalm6+FUBP1, or Nalm6+RUNX1+FUBP1 human cell lines (n = 5–10 per group). The general condition of mice was monitored daily until experiment
ended. Kaplan-Meier survival curves were plotted. P-value was assessed with Mantel-Cox tests compared to mice xenografted with Nalm6control. (C)
Inhibition curves from Nalm6control, Nalm6+RUNX1, Nalm6+FUBP1, and Nalm6+RUNX1+FUBP1 cell lines treated with 100 ng/ml of SCF and with growing
concentrations of imatinib mesylate (0–10 M) for 48h. Each point is the mean of four biological replicates ± S.E.M. Statistical significance was assessed
at 10 M compared to Nalm6control by Mann–Whitney tests (*P < 0.05).
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